Exploiting allele-specific transcriptional effects of subclonal copy number alterations for genotype-phenotype mapping in cancer cell populations.

Somatic copy number alterations drive aberrant gene expression in cancer cells. In tumors with high levels of chromosomal instability, subclonal copy number alterations (CNAs) are a prevalent feature which often result in heterogeneous cancer cell populations with distinct phenotypes

Déclaration de conflit d'intérêts

Competing Interests SPS is a shareholder of Imagia Canexia Health Inc. and is a consultant to AstraZeneca Inc., outside the scope of this work.